Regulatory and ethical considerations for ensuring clinically relevant trial populations 

The future of clinical research depends on its ability to generate reliable, real-world data that accurately reflects all affected patient populations. By embedding population science strategies into study designs, fostering regulatory alignment and embracing digital and decentralized trial innovations, the industry can advance both scientific rigor and patient outcomes.

This white paper explores:

• Empowering patients through inclusive study designs
• Overcoming challenges to achieve clinically relevant trial populations
• Embedding representation in clinical development strategy

The PPD™ clinical research business of Thermo Fisher Scientific is committed to supporting our customers in developing clinical trial strategies that generate robust and comprehensive data reflective of real-world patient populations. We provide targeted support to trial sites with a proven ability to engage clinically relevant patient populations, including additional resources, training and infrastructure investments